![](/img/cover-not-exists.png)
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
Smolen, Josef S, Choe, Jung-Yoon, Prodanovic, Nenad, Niebrzydowski, Jaroslaw, Staykov, Ivan, Dokoupilova, Eva, Baranauskaite, Asta, Yatsyshyn, Roman, Mekic, Mevludin, Porawska, Wieslawa, Ciferska, HanLanguage:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2017-211741
Date:
October, 2017
File:
PDF, 739 KB
english, 2017